RCS - Eco Animal Health Gp - Investor Presentation

ECO Animal HealthAnnouncement

27/11/2023 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231127:nRSa7512Ua&default-theme=true

RNS Number : 7512U  Eco Animal Health Group PLC  27 November 2023

ECO Animal Health Group plc

(''ECO" or the "Group") (AIM: EAH)

Investor Presentation covering Interim Results

ECO Animal Health Group plc, a leader in the development, registration and
marketing of pharmaceutical products for global animal health markets, is
pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will
be conducting a live presentation covering the Group's interim results for the
period ended 30 September 2023.

The online presentation will take place on Wednesday 29 November at
3.00pm UK time. This event is open to all existing and potential
shareholders and registration is free. Questions can be submitted during the
presentation and will be addressed at the end of it.

To register for the event, please click here
(https://www.equitydevelopment.co.uk/news-and-events/eco-investor-presentation-29nov2023)

A video recording of the presentation will be available shortly
afterwards here
(https://www.equitydevelopment.co.uk/research/tag/eco-animal-health)

 

Contacts:

 

 ECO Animal Health Group plc  020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                 020 3934 6630

 Graham Herring

 Zach Cohen

 Equity Development           020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

 

ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUBAKRONUAURA